Medical Doctor for a PhD project, Center of Clinical Transfusion, Leiden
MK 48-14 EXTEW 2
High amounts of blood products are given to patients with hemato-oncologic diseases, either because of induction chemotherapy or autologous/ allogeneic stem cell transplantation (SCT) or because of the underlying disease itself (such as myelodysplastic syndrome. In hemato-oncologic patients platelet transfusions are currently been given with regard to evidence based studies, however red blood cell (RBC) transfusion strategies vary considerably between various hemato-oncologic patients as well as between treatment centers. Associated risks of transfusions, like transmission of infectious diseases, transfusion reactions, immunomodulation and iron deposition may have detrimental effects on the outcome of hemato-oncologic patients. Moreover, these risks can add up since these patients receive multiple transfusions, while disease related survival of these patients has improved drastically. Studies to delineate unwanted (long-term) side effects of the given transfusion support are therefore more and more needed.
In the Netherlands for almost 2 decades, HOVON (Dutch-Belgian Cooperative Trial Group for Hematology Oncology) establishes and implements clinical trials regarding malignant hematological disorders. The HOVON data center collects the data of these clinical trials, nowadays including thousands of closely monitored hemato-oncologic patients. By analysis of transfusion data from HOVON trials concerning treatments of acute leukemia, myelodysplastic syndrome or the employment of autologous or allogeneic SCT, we will be able to group patients per treatment and center dependent transfusion support. With this approach and because of the sheer size of the datasets, the attributable consequences of the transfusion support strategy for treatment outcome can be determined.
Furthermore, it will allow to assess the adherence to the current guideline of prevention of iron overload in heavily transfused hemato-oncologic patients, to monitor possible iron overload dependent organ damage and to perform cohort studies among long-term survivors with both high transfusion support and low transfusion support. The present project studies the impact of blood management in hemato-oncologic patients it is strongly aligned with Sanquin#s mission to ensure safe and efficient blood supply in the Netherlands. It combines a unique collaboration between Sanquin Research and HOVON data center.
You will work in a multidisciplinary international team that focuses on clinical transfusion reasearch. This team is embedded in the Center of Clinical Transfusion Research, where about 20 fellow colleagues (epidemiologists, clinicians and PhD students) are studying various aspects of blood and blood component transfusion in relation to patients. The department#s research program benefits from the excellent research facilities at both Sanquin and LUMC (University Medical Center Leiden), which include training in Epidemiology and Immunohematology.
We are looking for:
We are looking for a highly motivated candidate who holds a masters degree in Medicine, speaks fluently Dutch and English and has a strong interest in hematology and/ or transfusion medicine. The candidate must have strong intellectual and organizing skills, in addition to experience or interest in Epidemiology.
- salary and conditions are conform CAO Sanquin;
- a 32 or 36 hour-week;
- reimbursement of travel expenses;
- a temporary appointment for a period of 3 years;
- working hours are fixed by mutual agreement;
- 8,33% year-end;
- by full-time employment 201 vacation hours.
For further information about this position, please contact: dr M.G.J. van Kraaij, phone number: 024-5123986, or Prof dr J.J. Zwaginga, phone number: 071-5265129, or Prof dr J.G. van der Bom, phone number: 06-17540335.
Solliciteer direct online met je CV en motivatie via bovenstaande sollicitatiebutton.